Table 3 Recommendations for antifungal prophylaxis in patients with MDS, CML, and MPN.

From: Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)

Population

Intervention

SoR

QoE

ECIL 5-6

MDS low-/intermediate

No chemotherapy

Any prophylaxis

D

I

No recommendation

MDS Intermediate/High treated as AML with intensive chemotherapy

posaconazole prophylaxis

300 mg q24 p.o. (q12h on day 1)

A

I

As for AML

MDS Intermediate/High Treated with Azacytidine

posaconazole prophylaxis during the first 4 azacytidine courses

B

IIu

No recommendation

CML

Treated with TKIs

Any prophylaxis

D

I

No recommendation

MPN

No chemotherapy

Any prophylaxis

D

I

No recommendation

MPN

Treated with Ruxolitinib

Any prophylaxis

D

I

No recommendation

  1. MDS Myelodysplastic Syndromes, CML Chronic Myeloid Leukemia, MPN Myeloproliferative Neoplasms, AML acute myeloid leukemia, TKIs tyrosine kinase inhibitors.
Back to article page